Fernando Antoñanzas Villar (F Antoñanzas, Fernando Antonanzas, Fernando Antoñanzas)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 13

Top Topics

Systematic Review

Respiratory Tract

Top Venues

PharmacoEconomics

Expert review of pharmacoeconomics & outcomes research

Health economics review

The European journal of health economics : HEPAC : health economics in prevention and care

This page only lists publications with an associated author ORCID identifier.

Publications

Stefano Capri, Fernando Antoñanzas Villar, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research 23 (4) (2023)
Stefano Capri, Fernando Antoñanzas Villar, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research 23 (4) (2023)
Stefano Capri, Fernando Antoñanzas Villar, Rosella Levaggi
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert review of pharmacoeconomics & outcomes research (2023)
Fernando Antoñanzas Villar, Carmelo A Juárez-Castelló, R Rodríguez-Ibeas
Does diagnostic testing always decrease antibiotics prescriptions? The European journal of health economics : HEPAC : health economics in prevention and care (2022)
Simon van der Pol, Paula Rojas Garcia, Maarten Jacobus Postma, Fernando Antoñanzas Villar, Antoinette D I van Asselt
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review. PharmacoEconomics 39 (12) (2021)
Fernando Antoñanzas Villar
Hispa-NICE: A Pipe Dream or a Realistic and Necessary Initiative? PharmacoEconomics 39 (5) (2021)
Fernando Antoñanzas Villar, Carmelo A Juárez-Castelló, R Rodríguez-Ibeas
Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model. Health economics review 11 (1) (2021)
Paula Rojas Garcia, Fernando Antoñanzas Villar
Analysis of the Prescription of Antibiotics During the Implementation of COVID-19 Personal Protection Measures in a Regional Health System. ClinicoEconomics and outcomes research : CEOR 13 (2021)
Fernando Antoñanzas Villar, Carmelo Juárez-Castelló, Reyes Lorente, Roberto Rodríguez-Ibeas
The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. PharmacoEconomics 37 (12) (2020)
Reyes Lorente, Fernando Antoñanzas Villar, Roberto Rodriguez-Ibeas
Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists. Health economics review 9 (1) (2019)
Fernando Antoñanzas Villar, Roberto Rodríguez-Ibeas, Carmelo A Juárez-Castelló
Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails? PharmacoEconomics 36 (7) (2019)
Fernando Antoñanzas Villar, Robert Terkola, Paul M Overton, Natalie Shalet, Maarten Postma
Defining and Measuring the Affordability of New Medicines: A Systematic Review. PharmacoEconomics 35 (8) (2018)
Fernando Antoñanzas Villar, Robert Terkola, Maarten Postma
The Value of Medicines: A Crucial but Vague Concept. PharmacoEconomics 34 (12) (2017)